Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(2):98-100; doi:10.1093/jnci/92.2.98
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jenks, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jenks, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 2, 98-100, January 19, 2000
© 2000 Oxford University Press

NEWS

Gene Therapy Death — "Everyone Has to Share in the Guilt"

Susan Jenks

The unexpected gene therapy death of 18-year-old Jesse Gelsinger has unleashed a public outcry over who is to blame.

And while there is no simple answer, there is also no shortage of possible candidates: the investigators at the University of Pennsylvania who carried out the experimental therapy; the local institutional review board that purportedly omitted animal data in the informed consent form; the government agencies that oversee gene therapy; and a biotechnology industry eager to cash in on a promising medical field.

"Everybody has to share in the guilt of what's happened here," said Abbey S. Meyers, president of the National Organization of Rare Disorders in New Fairfield, Conn., and a former member of the Recombinant DNA Advisory Committee, the federal group that initially recommended approval of the gene study to treat Gelsinger's rare liver disorder.



View larger version (146K):
[in this window]
[in a new window]
  		Abbey S. Meyers

 
Meyers was unable to attend last month's special 3-day meeting . . . [Full Text of this Article]

Jesse's Legacy

Behind Closed Doors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
N. Eliopoulos, R. F. Gagnon, M. Francois, and J. Galipeau
Erythropoietin Delivery by Genetically Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice with Chronic Renal Failure
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1576 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
C. Levine, R. Faden, C. Grady, D. Hammerschmidt, L. Eckenwiler, J. Sugarman, and on behalf of the Consortium to Examine Clinical Re
"Special Scrutiny": A Targeted Form of Research Protocol Review
Ann Intern Med, February 3, 2004; 140(3): 220 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Reid, E. Galanis, J. Abbruzzese, D. Sze, L. M. Wein, J. Andrews, B. Randlev, C. Heise, M. Uprichard, M. Hatfield, et al.
Hepatic Arterial Infusion of a Replication-selective Oncolytic Adenovirus (dl1520): Phase II Viral, Immunologic, and Clinical Endpoints
Cancer Res., November 1, 2002; 62(21): 6070 - 6079.
[Abstract] [Full Text] [PDF]